此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Screening fOR Throat Cancer (SORT)

2026年11月11日 更新者:Johns Hopkins University

SORT (Screening fOR Throat Cancer)

This study will screen people for biomarkers of Human Papillomavirus (HPV) to form a cohort of people who may be at increased risk of HPV-oropharyngeal cancer (HPV-OPC). The investigators will follow these individuals prospectively to evaluate risk for OPC.

研究概览

地位

尚未招聘

详细说明

This study will assess HPV16 biomarkers, including serum HPV16 E6 antibodies, plasma and oral HPV16 DNA, and ultrasound, to understand the feasibility and utility of HPV16 biomarker screening to identify those at increased risk of HPV-OPC. This study will screen approximately 2500 people. The focus of the study is to determine whether sequential testing for oral and plasma HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies among people with and without HIV. The study includes community screening, as well as biobank screening with longitudinal follow-up of those who screen positive.

Study Design Overview: This study has an initial screen that includes two populations: screening of biobank samples "biobank group" and screening of healthy members of the community "community group" which can be done via an in-person visit or via remote sample collection. The subset of participants with HPV16 biomarkers detected will be asked to join the longitudinal follow-up. During follow-up, participants will have more samples collected and have a neck ultrasound to look for any precancerous lesions.

The study is led by Dr. Amber D'Souza and Dr. Carole Fakhry (Johns Hopkins). Participants are being enrolled from the MWCCS cohort, from Baltimore, MD, and across the US. If interested, complete the study eligibility form at [link coming] or email hpv@jhu.edu with questions.

研究类型

观察性的

注册 (估计的)

2500

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Amber D'Souza, PhD
  • 电话号码:410-502-2583
  • 邮箱:gdsouza2@jhu.edu

学习地点

    • Maryland
      • Baltimore、Maryland、美国、21205
        • Johns Hopkins Hospital
        • 接触:
        • 首席研究员:
          • Amber D'Souza, PhD
        • 首席研究员:
          • Carole Fakhry, MD, MPH

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 至 69年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

男性

取样方法

非概率样本

研究人群

The study population will be drawn from multiple sources, including healthy men from the broader U.S. population interested in the study via online self-referral, website outreach, or study outreach, as well as participants from the MACS WIHS Combined Cohort Study (MWCCS).

描述

Inclusion Criteria:

  • Part I: Participants in Screening

To be eligible to participate in Part I of this study, an individual must meet the following criteria:

Community and Internet Screen eligibility:

  • Male, 40-69 years old
  • Willing to self-collect or come in person to collect screening biospecimens
  • Willing to be contacted to arrange follow-up visits, if determined to be eligible for follow-up
  • Ability to understand and the willingness to sign a written informed consent document

Biorepository Screen eligibility:

  • Male, 40-69 years old

  • Active participant within MWCCS

  • Willing to be contacted to arrange follow-up visits, if determined to be eligible for follow-up

  • Ability to understand and the willingness to sign a written informed consent document

    • Part II: Participants in Follow-Up

To be eligible to participate in Part II of this study, an individual must meet all of the following criteria:

  • HPV16 biomarker detected in Part I screen
  • Willingness to complete annual follow-up visits

Exclusion Criteria:

  • Part I: Participants in Screening

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Presence of medical or psychiatric condition affecting ability to give voluntary, informed consent.

  • Participants who do not speak English cannot enroll because the consent and study survey are only available in English. However, if there is a hearing, literacy, or minor fluency issue and the participant requests assistance from a family member or the study coordinator, this individual may still enroll and receive this assistance to ensure the participant fully hears and understands everything being asked.

  • History of head and neck cancer

    • Part II: Participants in Follow-Up

An individual who meets any of the following criteria will be excluded from participation in this part of the study:

• Unable to complete annual follow-up visits

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
Prospective Observational Cohort

Prospective cohort of adult male participants from two groups: community group (see eligibility form) an biobank group (enrolled from MWCCS cohort). Both groups will undergo initial screening, with eligible participants continuing onto follow-up testing, which may include blood collection, oral rinse collection, anal Pap smear, ultrasound imaging, and surveys.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
HPV16 E6 antibodies present or absent in serum sample
大体时间:Baseline to end of three-year follow-up

To determine whether sequential testing for oral or plasma HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies.

Baseline to end of three-year follow-up
Oral HPV16 DNA present or absent
大体时间:Baseline to end of three-year follow-up

To determine whether sequential testing for oral HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies.

Baseline to end of three-year follow-up

次要结果测量

结果测量
措施说明
大体时间
Feasibility of community screening
大体时间:Baseline to end of three-year follow-up

To assess whether primary screening in a community setting of healthy individuals can lead to at least 80% of those with HPV16 E6 antibodies identified agreeing to complete follow-up biomarker collection and ultrasound for secondary screening.

Baseline to end of three-year follow-up

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年1月1日

初级完成 (估计的)

2032年1月1日

研究完成 (估计的)

2037年1月1日

研究注册日期

首次提交

2026年11月11日

首先提交符合 QC 标准的

2026年11月11日

首次发布 (实际的)

2026年11月17日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The investigators will utilize a plan for the controlled release, management, and sharing of data. Data will be made available through a study research proposal process.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅